Sugi Predict

Sugi Predict / Compounds / SCHEMBL4594871

SCHEMBL4594871

SCHEMBL4594871

CCCCCN1CC=CCC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 7/20 0.51
▸ MAOB P27338 3/20 0.44
▸ GNAI3 P08754 3/20 0.42
▸ GNAO1 P09471 3/20 0.42
▸ GNAI1 P63096 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ GUSB P08236 2/20 0.37
▸ EBP Q15125 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8266619 0.98 MAOA (0.50) MAOAMAOBGNAI3GNAO1GNAI1
SCHEMBL8169120 0.94 MAOA (0.53) MAOAMAOBGNAI3GNAO1GNAI1
Urea SCHEMBL4758822 0.89 MAOA (0.44) MAOAMAOBGNAI3GNAO1GNAI1
SCHEMBL8288234 0.85 — —
SCHEMBL5174920 0.84 ALDH1A1 (0.45) GNAI3GNAO1GNAI1ALDH1A1CYP1A2
SCHEMBL21862404 0.82 GNAI3 (0.46) GNAI3GNAO1GNAI1KDM4EGAA
SCHEMBL1081412 0.81 GNAO1 (0.44) GNAI3GNAO1GNAI1ALDH1A1CYP1A2
SCHEMBL7363127 0.79 MAOA (0.51) MAOAMAOB
SCHEMBL7068718 0.79 MAOA (0.51) MAOAMAOB
SCHEMBL1098542 0.79 MAOA (0.51) MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297799-B2 Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof SANOFI-AVENTIS (FR) 2007-11-20 — — US claimed
US-20070054931-A1 PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF SANOFI-AVENTIS (FR) 2007-03-08 — — US claimed
US-20050222187-A1 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines SANOFI-AVENTIS (FR) 2005-10-06 — — US claimed
US-20040122032-A1 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines SANOFI-AVENTIS (FR) 2004-06-24 — — US claimed
EP-0950053-B1 NEW DERIVATIVES OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS SANOFI SYNTHELABO (FR) 2003-06-11 — — EP claimed
EP-0837848-B1 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY SANOFI SYNTHELABO (FR) 2002-09-11 — — EP claimed
EP-0950049-B1 DIPHENYL ALKYL-TETRAHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI SYNTHELABO (FR) 2001-10-17 — — EP claimed
EP-0950048-B1 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE SANOFI SYNTHELABO (FR) 2001-06-27 — — EP claimed
US-6124318-A Diphenylalkyl-tetrahydropyridines, process for their preparation, and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2000-09-26 — — US claimed
US-6034090-A 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease SANOFI-SYNTHLABO (FR) 2000-03-07 — — US claimed
US-5981754-A TREATMENT OF ANOXIA, ALZHEIMER'S DISEASE, SENILE DEMENTIA, SUBCORTICAL DEMENTIA SUCH AS HUNTINGTON'S CHOREA AND PARKINSON'S DISEASE, DEMENTIA CAUSED BY AIDS, NEUROPATHY SANOFI (FR) 1999-11-09 — — US claimed
EP-0950049-A1 DIPHENYL ALKYL-TETRAHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI-SYNTHELABO (FR) 1999-10-20 — — EP claimed
EP-0950053-A1 USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS SANOFI (FR) 1999-10-20 — — EP claimed
WO-1998028274-A1 USE OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINS SANOFI (FR) 1998-07-02 — — WO claimed
WO-1998025904-A1 DIPHENYL ALKYL-TETRAHYDROPYRIDINES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI (FR) 1998-06-18 — — WO claimed
EP-0837848-A1 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY SANOFI (FR) 1998-04-29 — — EP claimed
WO-1997001536-A1 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY SANOFI (FR) 1997-01-16 — — WO claimed
EP-3022180-B1 UV ABSORBING COMPOUNDS, COMPOSITIONS COMPRISING SAME AND USES THEREOF CORAL SUNSCREEN PTY LTD (AU) 2022-02-23 — — EP disclosed
US-4236009-A Method of preparing 4A-arylhexahydro-1H-2-pyrindines and 4A-aryloctahydroisoquinolines ELI LILLY AND COMPANY (US) 1980-11-25 — — US disclosed
US-4188396-A ANTIDEPRESSANTS CIBA-GEIGY CORPORATION (US) 1980-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122032-A1 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines KCNH1, KCNJ2, CACNA1B MAOA 383/4885MAOB 395/4885GNAI3 1694/4885
US-20070054931-A1 PREPARATION OF BENZOYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES AND USE THEREOF BDNF, KCNH1, GABRA6 MAOA 408/4885MAOB 375/4885GNAI3 1638/4885
US-20050222187-A1 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines KCNH1, ATP6V1B2, KCNJ6 MAOA 287/4885MAOB 265/4885GNAI3 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.